The endocrine-metabolic effects of hrGH and insulin-like growth factor-1 (IGF-1) therapy are well known in patients with pituitary defects and primary IGF-1 deficiency, respectively. Here, IGF1 is linked to hyperinsulinemic hypoglycemia, familial, 4.